Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15917203 | 1.00 | POLB (0.48) | POLBRECQLKDM4EL3MBTL1ALOX5AP | |
| SCHEMBL15918283 | 1.00 | POLB (0.48) | POLBRECQLKDM4EL3MBTL1ALOX5AP | |
| SCHEMBL1925462 | 0.82 | POLB (0.49) | POLBRECQLGBA1ALDH1A1PLCG1 | |
| SCHEMBL1926174 | 0.82 | POLB (0.49) | POLBRECQLGBA1ALDH1A1PLCG1 | |
| SCHEMBL15915636 | 0.81 | RECQL (0.54) | POLBRECQLALOX5APFEN1GBA1 | |
| SCHEMBL15915633 | 0.81 | RECQL (0.54) | POLBRECQLALOX5APFEN1GBA1 | |
| SCHEMBL15915901 | 0.81 | RECQL (0.54) | POLBRECQLALOX5APFEN1GBA1 | |
| SCHEMBL15914767 | 0.80 | GBA1 (0.51) | POLBRECQLALOX5APFEN1GBA1 | |
| SCHEMBL15915137 | 0.80 | GBA1 (0.51) | POLBRECQLALOX5APFEN1GBA1 | |
| SCHEMBL15914770 | 0.80 | GBA1 (0.51) | POLBRECQLALOX5APFEN1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495359-A1 | FLAP MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| EP-3070085-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| EP-3070085-A1 | FLAP MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-20150259357-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-17 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259357-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | POLB 1233/4885RECQL 254/4885KDM4E 1802/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | POLB 1233/4885RECQL 254/4885KDM4E 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.